Cyclopharm (ASX:CYC) on pathway to US sales

Published: Dec. 10, 2020, 10:20 p.m.

11 Dec 2020 - Cyclopharm Limited (ASX:CYC) CEO & Managing Director James McBrayer talks about USFDA approval for Technegas, the company's USA commercialisation plan, and opportunities beyond its key diagnostic market for pulmonary embolism.